000710.SZ
Berry Genomics Co., Ltd.
SZSE · Healthcare · M 科研服务 · CN
CNY 9.70
−5.92%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 922.3M | 929.8M | 1.1B | 1.2B | 1.4B |
| Cost of Revenue | 520.6M | 528.6M | 572.9M | 636.2M | 783.6M |
| Gross Profit | 401.7M | 401.2M | 505.3M | 515.2M | 584.4M |
| Operating Expenses | |||||
| R&D Expense | 107.1M | 104.4M | 95.4M | 110.0M | 106.7M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 163.6M | 157.8M | 148.7M | 141.6M | 197.8M |
| Selling & Marketing Expense | 209.6M | 206.5M | 236.8M | 292.5M | 303.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 491.6M | 480.6M | 499.6M | 567.2M | 634.3M |
| Cost and Expenses | 1.0B | 1.0B | 1.1B | 1.2B | 1.4B |
| Operating Income (EBIT) | (201.9M) | (187.3M) | (166.6M) | (450.7M) | (280.0M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (203.4M) | (189.6M) | (170.8M) | (453.4M) | (276.4M) |
| Income Tax Expense | 6.3M | 6.7M | 17.4M | (28.2M) | (30.0M) |
| Bottom Line | |||||
| Net Income | (210.1M) | (196.8M) | (192.4M) | (427.2M) | (248.9M) |
| Earnings from Cont. Ops | (209.7M) | (196.3M) | (188.2M) | (425.3M) | (246.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (210.1M) | (196.8M) | (192.4M) | (427.2M) | (248.9M) |
| Per Share | |||||
| Basic EPS | (CN¥0.60) | (CN¥0.56) | (CN¥0.54) | (CN¥1.21) | (CN¥0.81) |
| Diluted EPS | (CN¥0.60) | (CN¥0.56) | (CN¥0.54) | (CN¥1.21) | (CN¥0.81) |
| Revenue Per Share | CN¥2.80 | CN¥2.63 | CN¥3.05 | CN¥3.26 | CN¥4.45 |
| Shares | |||||
| Basic Shares Outstanding | 329.0M | 353.5M | 353.5M | 353.5M | 307.3M |
| Diluted Shares Outstanding | 329.0M | 353.5M | 353.5M | 353.5M | 307.3M |
| Profitability Metrics | |||||
| EBITDA | — | (109.7M) | (81.1M) | (341.0M) | (175.3M) |
| D&A | — | 77.6M | 85.6M | 109.7M | 104.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026